JP2013527449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013527449A5 JP2013527449A5 JP2013508512A JP2013508512A JP2013527449A5 JP 2013527449 A5 JP2013527449 A5 JP 2013527449A5 JP 2013508512 A JP2013508512 A JP 2013508512A JP 2013508512 A JP2013508512 A JP 2013508512A JP 2013527449 A5 JP2013527449 A5 JP 2013527449A5
- Authority
- JP
- Japan
- Prior art keywords
- cer
- lipid
- glccer
- laccer
- apolipoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 61
- YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 claims 61
- 150000002632 lipids Chemical class 0.000 claims 32
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 24
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 24
- 239000000523 sample Substances 0.000 claims 23
- QYWVASPEUXEHSY-NNRNTGNWSA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-(docosanoyl)sphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QYWVASPEUXEHSY-NNRNTGNWSA-N 0.000 claims 22
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 21
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 21
- 208000024172 Cardiovascular disease Diseases 0.000 claims 21
- 238000000034 method Methods 0.000 claims 21
- VJLLLMIZEJJZTE-NNTBDIJYSA-N beta-D-glucosyl-N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VJLLLMIZEJJZTE-NNTBDIJYSA-N 0.000 claims 18
- 201000001320 Atherosclerosis Diseases 0.000 claims 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 16
- MKOKWBRPIBQYJJ-WZBOJYASSA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-N-[(15Z)-tetracosenoyl]sphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MKOKWBRPIBQYJJ-WZBOJYASSA-N 0.000 claims 14
- BPLYVSYSBPLDOA-WVILEFPPSA-N N-tetracosanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)CCCCCCCCCCCCCCC BPLYVSYSBPLDOA-WVILEFPPSA-N 0.000 claims 13
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims 12
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims 12
- 239000013068 control sample Substances 0.000 claims 11
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 9
- 235000012000 cholesterol Nutrition 0.000 claims 8
- ZJVVOYPTFQEGPH-UHFFFAOYSA-N 102917-80-6 Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC ZJVVOYPTFQEGPH-UHFFFAOYSA-N 0.000 claims 7
- ZJVVOYPTFQEGPH-AUTSUKAISA-N N-tetracosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC ZJVVOYPTFQEGPH-AUTSUKAISA-N 0.000 claims 7
- YMYQEDCYNANIPI-DYJXBSQNSA-N beta-D-glucosyl-N-octadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YMYQEDCYNANIPI-DYJXBSQNSA-N 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 102000009081 Apolipoprotein A-II Human genes 0.000 claims 6
- 108010087614 Apolipoprotein A-II Proteins 0.000 claims 6
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims 6
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 6
- UIKPUUZBQYTDRX-YRRBDHRDSA-N alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 UIKPUUZBQYTDRX-YRRBDHRDSA-N 0.000 claims 6
- 108010064635 HDL cholesteryl ester Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 5
- 108010023302 HDL Cholesterol Proteins 0.000 claims 4
- 108010028554 LDL Cholesterol Proteins 0.000 claims 4
- SXPRAKSDHOEHIG-ZESVVUHVSA-N N-docosanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)CCCCCCCCCCCCCCC SXPRAKSDHOEHIG-ZESVVUHVSA-N 0.000 claims 4
- XWBWIAOWSABHFI-NUKVNZTCSA-N N-icosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC XWBWIAOWSABHFI-NUKVNZTCSA-N 0.000 claims 4
- VODZWWMEJITOND-NXCSZAMKSA-N N-octadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC VODZWWMEJITOND-NXCSZAMKSA-N 0.000 claims 4
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 4
- KEPQASGDXIEOIL-UHFFFAOYSA-N (2S,3R)-N-(docosanoate)-1,3-dihydroxy-2-amino-octadeca-4-(E)-ene Natural products CCCCCCCCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC KEPQASGDXIEOIL-UHFFFAOYSA-N 0.000 claims 3
- -1 C er (d18: 0/22: 0) Chemical compound 0.000 claims 3
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 3
- OAHFTKWSJGVMTG-MBIABJCFSA-N N-(9Z-hexadecenoyl)sphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](COP([O-])(=O)OCC[N+](C)(C)C)NC(=O)CCCCCCC\C=C/CCCCCC OAHFTKWSJGVMTG-MBIABJCFSA-N 0.000 claims 3
- KEPQASGDXIEOIL-GLQCRSEXSA-N N-docosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC KEPQASGDXIEOIL-GLQCRSEXSA-N 0.000 claims 3
- QEDPUVGSSDPBMD-XTAIVQBESA-N N-lignoceroylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC QEDPUVGSSDPBMD-XTAIVQBESA-N 0.000 claims 3
- KYICBZWZQPCUMO-PSALXKTOSA-N N-myristoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](COP([O-])(=O)OCC[N+](C)(C)C)NC(=O)CCCCCCCCCCCCC KYICBZWZQPCUMO-PSALXKTOSA-N 0.000 claims 3
- DOJNPEGQAGROHH-JIILTNDZSA-N alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/16:0) Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O[C@@H]4O[C@H](CO)[C@H](O)[C@H](O[C@@]5(C[C@H](O)[C@@H](NC(C)=O)[C@@H](O5)[C@H](O)[C@H](O)CO)C(O)=O)[C@H]4O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@H](O)[C@@H](NC(C)=O)[C@@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC DOJNPEGQAGROHH-JIILTNDZSA-N 0.000 claims 3
- NURCPIMQAUMKKZ-ORNMTBJMSA-N alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/16:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 NURCPIMQAUMKKZ-ORNMTBJMSA-N 0.000 claims 3
- SIJZEDYROBAHFV-KURPOCNNSA-N alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/20:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 SIJZEDYROBAHFV-KURPOCNNSA-N 0.000 claims 3
- FWACHXQPQUXIMV-UKBBABHFSA-N alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/21:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 FWACHXQPQUXIMV-UKBBABHFSA-N 0.000 claims 3
- WVVWYQOPRPVQFM-QODCBXQFSA-N alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/22:1(13Z)) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 WVVWYQOPRPVQFM-QODCBXQFSA-N 0.000 claims 3
- 230000003796 beauty Effects 0.000 claims 3
- FGJIXPPBZNPEHW-CRMMDXJYSA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-N-eicosanoylsphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 FGJIXPPBZNPEHW-CRMMDXJYSA-N 0.000 claims 3
- VOZHMDQUIRUFQW-LOTHNZFDSA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-N-octadecanoylsphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 VOZHMDQUIRUFQW-LOTHNZFDSA-N 0.000 claims 3
- 229920000080 bile acid sequestrant Polymers 0.000 claims 3
- 230000008859 change Effects 0.000 claims 3
- 150000001840 cholesterol esters Chemical class 0.000 claims 3
- 230000034994 death Effects 0.000 claims 3
- 231100000517 death Toxicity 0.000 claims 3
- 229940125753 fibrate Drugs 0.000 claims 3
- 235000021588 free fatty acids Nutrition 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000008569 process Effects 0.000 claims 3
- 230000009467 reduction Effects 0.000 claims 3
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 101710095342 Apolipoprotein B Proteins 0.000 claims 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 2
- 102000007592 Apolipoproteins Human genes 0.000 claims 2
- 108010071619 Apolipoproteins Proteins 0.000 claims 2
- 102000018616 Apolipoproteins B Human genes 0.000 claims 2
- 108010027006 Apolipoproteins B Proteins 0.000 claims 2
- CJROVRTUSFQVMR-GVOPMEMSSA-N N-hexacosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC CJROVRTUSFQVMR-GVOPMEMSSA-N 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims 2
- 229960003765 fluvastatin Drugs 0.000 claims 2
- 238000004949 mass spectrometry Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical group Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 229920001268 Cholestyramine Polymers 0.000 claims 1
- 229920002905 Colesevelam Polymers 0.000 claims 1
- 229920002911 Colestipol Polymers 0.000 claims 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- 241000283080 Proboscidea <mammal> Species 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- MZZLGJHLQGUVPN-HAWMADMCSA-N anacetrapib Chemical compound COC1=CC(F)=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]1C MZZLGJHLQGUVPN-HAWMADMCSA-N 0.000 claims 1
- 229950000285 anacetrapib Drugs 0.000 claims 1
- 239000012491 analyte Substances 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229960001214 clofibrate Drugs 0.000 claims 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims 1
- 229960001152 colesevelam Drugs 0.000 claims 1
- 229960002604 colestipol Drugs 0.000 claims 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000000612 dual polarization interferometry Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
- 229960000815 ezetimibe Drugs 0.000 claims 1
- 229960002297 fenofibrate Drugs 0.000 claims 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 1
- 238000001506 fluorescence spectroscopy Methods 0.000 claims 1
- 229960003627 gemfibrozil Drugs 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- IMNTVVOUWFPRSB-JWQCQUIFSA-N sch-48461 Chemical compound C1=CC(OC)=CC=C1[C@H]1N(C=2C=CC(OC)=CC=2)C(=O)[C@@H]1CCCC1=CC=CC=C1 IMNTVVOUWFPRSB-JWQCQUIFSA-N 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical group COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 claims 1
- 229950004514 torcetrapib Drugs 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33146310P | 2010-05-05 | 2010-05-05 | |
| US61/331,463 | 2010-05-05 | ||
| EP10162066.4 | 2010-05-05 | ||
| EP10162066.4A EP2385374B2 (en) | 2010-05-05 | 2010-05-05 | Lipidomic biomarkers for atherosclerosis and cardiovascular disease |
| PCT/EP2011/057254 WO2011138419A1 (en) | 2010-05-05 | 2011-05-05 | Lipidomic biomarkers for atherosclerosis and cardiovascular disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013527449A JP2013527449A (ja) | 2013-06-27 |
| JP2013527449A5 true JP2013527449A5 (https=) | 2015-02-12 |
| JP5871244B2 JP5871244B2 (ja) | 2016-03-01 |
Family
ID=42315849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508512A Active JP5871244B2 (ja) | 2010-05-05 | 2011-05-05 | アテローム性動脈硬化症及び心脈管系疾患のリピドームバイオマーカー |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US9046538B2 (https=) |
| EP (3) | EP2385374B2 (https=) |
| JP (1) | JP5871244B2 (https=) |
| CN (1) | CN102971633B (https=) |
| CA (1) | CA2798238C (https=) |
| DK (2) | DK2385374T4 (https=) |
| ES (2) | ES2455124T5 (https=) |
| NO (2) | NO2385374T3 (https=) |
| WO (1) | WO2011138419A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9046540B2 (en) * | 2008-09-29 | 2015-06-02 | Plaxgen Inc. | Assay, composition and non-enzymatic mechanism of statin in modulating lipid metabolism |
| WO2011063470A1 (en) | 2009-11-27 | 2011-06-03 | Baker Idi Heart And Diabetes Institute Holdings Limited | Lipid biomarkers for stable and unstable heart disease |
| EP2529235B1 (en) * | 2010-01-29 | 2019-03-06 | Metanomics GmbH | Means and methods for diagnosing heart failure in a subject |
| NO2385374T3 (https=) | 2010-05-05 | 2014-06-07 | ||
| CN108445241B (zh) * | 2010-06-20 | 2021-11-02 | 佐拉生物科学公司 | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 |
| US8765479B1 (en) * | 2011-03-13 | 2014-07-01 | Atherotech, Inc. | Methods for determining the risk of coronary heart disease and clinical manifestations of coronary heart disease |
| US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| EP2592422A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| EP2642295A1 (en) * | 2012-03-22 | 2013-09-25 | Nestec S.A. | 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 40:1 as biomarker for healthy ageing |
| EP2642293A1 (en) | 2012-03-22 | 2013-09-25 | Nestec S.A. | 9-oxo-octadecadienoic acid (9-oxo-HODE)as as biomarker for healthy ageing |
| EP2667197B1 (en) * | 2012-05-25 | 2015-09-16 | Zora Biosciences OY | Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition |
| CN103149312B (zh) * | 2013-02-05 | 2015-02-04 | 东北农业大学 | 一种利用超高效液相色谱串联四级杆质谱分析婴儿乳粉中唾液酸的方法 |
| EP2778686B1 (en) * | 2013-03-13 | 2016-07-27 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Lipidomics of familial longevity |
| CA2926592A1 (en) * | 2013-11-14 | 2015-05-21 | Nestec S.A. | Lipid biomarkers of healthy ageing |
| KR101660328B1 (ko) | 2014-01-14 | 2016-09-27 | 한국과학기술연구원 | 심혈관 질환 진단용 바이오 마커 |
| WO2015156844A1 (en) | 2014-04-10 | 2015-10-15 | MEP Equine Solutions LLC | Method for the quantification of parasite eggs in feces |
| US9347960B2 (en) * | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
| CN107110939B (zh) * | 2014-09-11 | 2021-05-14 | 力保科学公司 | 用于测定心血管疾病或事件的风险参数的系统 |
| WO2016100549A2 (en) * | 2014-12-16 | 2016-06-23 | Washington University | Ceramides for evaluating risk of cardiovascular disease |
| HUE069048T2 (hu) * | 2015-01-09 | 2025-02-28 | Global Genomics Group Llc | Vér alapú biomarkerek ateroszklerotikus koszorúér-betegség diagnosztizálására |
| EP3121599A1 (en) * | 2015-07-23 | 2017-01-25 | Medizinische Hochschule Hannover | Analysis for atherosclerosis |
| US20180238914A1 (en) * | 2015-08-19 | 2018-08-23 | Metanomics Gmbh | Means and methods for diagnosing cardiac disease in a subject |
| WO2017028308A1 (en) * | 2015-08-20 | 2017-02-23 | Bgi Shenzhen | Biomarkers for coronary heart disease |
| WO2017097852A2 (en) * | 2015-12-07 | 2017-06-15 | Zora Biosciences Oy | Use of ceramides and lpls in diagnosing cvd |
| CN105486778B (zh) * | 2016-01-25 | 2017-11-03 | 齐炼文 | 诊断区分稳定型心绞痛和急性冠脉综合征的代谢标志物 |
| CN105445408B (zh) * | 2016-01-25 | 2018-06-12 | 齐炼文 | 诊断区分冠状动脉粥样硬化和稳定型心绞痛的代谢标志物 |
| CN108872404A (zh) * | 2017-05-09 | 2018-11-23 | 中国科学院上海生命科学研究院 | 超长链饱和脂肪酸或其检测试剂在代谢综合征患病风险预测中的应用 |
| CN107144624B (zh) * | 2017-05-15 | 2021-01-05 | 中国科学院生态环境研究中心 | 甄别二氧化硅颗粒来源的方法 |
| TWI835735B (zh) * | 2017-06-12 | 2024-03-21 | 比利時商健生藥品公司 | 減少或預防第ii型糖尿病患者中心血管事件之方法 |
| CN109870536B (zh) * | 2017-12-05 | 2021-08-10 | 中国科学院大连化学物理研究所 | 一种基于液相色谱-质谱联用的高覆盖脂质组学分析方法 |
| CN108037275A (zh) * | 2017-12-14 | 2018-05-15 | 北京豪思生物科技有限公司 | 一种用于评估冠状动脉疾病的试剂盒 |
| WO2019119049A1 (en) * | 2017-12-20 | 2019-06-27 | Baker Heart and Diabetes Institute | Method of predicting drug therapeutic responder status and methods of treatment |
| CN110433282B (zh) * | 2018-05-04 | 2023-03-14 | 上海交通大学医学院附属瑞金医院 | 胰高血糖素样肽-1在制备治疗钙化性主动脉瓣疾病药物方面的应用 |
| US12399188B2 (en) | 2018-12-06 | 2025-08-26 | Zora Biosciences Oy | Biomarkers for cardiovascular events |
| US20220214367A1 (en) * | 2019-04-15 | 2022-07-07 | Board Of Regents, The University Of Texas System | Calibration methods and compositions for biomolecule analysis |
| WO2020242796A1 (en) * | 2019-05-28 | 2020-12-03 | Ohio University | Assays and methods for screening for cardiovascular disease using ldl subclasses and endothelial nitric oxide/peroxynitrite balance |
| CN112147344B (zh) * | 2020-10-30 | 2021-07-13 | 河北医科大学第二医院 | 动脉粥样硬化性脑梗死的代谢标志物及其在诊疗中的应用 |
| CN112305119B (zh) * | 2020-10-30 | 2021-08-17 | 河北医科大学第二医院 | 动脉粥样硬化性脑梗死的生物标志物及其应用 |
| CN112305124B (zh) * | 2020-10-30 | 2022-03-04 | 河北医科大学第二医院 | 一种生物标志物及其在疾病诊断中的应用 |
| CN112305122B (zh) * | 2020-10-30 | 2021-07-13 | 河北医科大学第二医院 | 代谢物标志物及其在疾病中的应用 |
| CN113782177A (zh) * | 2020-12-02 | 2021-12-10 | 北京市心肺血管疾病研究所 | 一种用于鉴别诊断冠心病患者斑块稳定性的数据处理装置、系统 |
| CN112630330B (zh) * | 2020-12-08 | 2021-12-21 | 河北医科大学第二医院 | 小分子物质在脑梗死诊断中的应用 |
| CA3217229A1 (en) * | 2021-04-21 | 2022-10-27 | Albert Einstein College Of Medicine | Methods of stabilizing the neuronal proteome against collapse and protecting vascular cells |
| CN113295793B (zh) * | 2021-05-20 | 2022-11-04 | 复旦大学附属中山医院 | 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用 |
| CN114113573B (zh) * | 2021-11-08 | 2022-11-11 | 中国医学科学院阜外医院 | 糖尿病患者早期预测心血管疾病(cvd)的生物标志物及其用途 |
| CN113960221B (zh) * | 2021-12-23 | 2022-02-25 | 中国中医科学院医学实验中心 | 基于粪便样本的胆汁酸全通路代谢轮廓的检测方法及其应用 |
| CN113960222B (zh) * | 2021-12-23 | 2022-02-25 | 中国中医科学院医学实验中心 | 基于血清样本的胆汁酸全通路代谢轮廓的检测方法及其应用 |
| CN114791459B (zh) * | 2022-03-29 | 2023-02-14 | 浙江苏可安药业有限公司 | 用于检测肺结核的血清代谢标志物及其试剂盒 |
| CN114705873B (zh) * | 2022-06-06 | 2022-08-26 | 首都医科大学宣武医院 | 脂质作为颈动脉粥样硬化斑块诊断标志物的用途 |
| CN115267214A (zh) * | 2022-08-10 | 2022-11-01 | 南方医科大学珠江医院 | 一种脂质代谢标志物、其筛选方法及其在颅内动脉瘤中的应用 |
| WO2024192471A1 (en) * | 2023-03-20 | 2024-09-26 | Baker Heart and Diabetes Institute | Methods of assessing metabolic health |
| CN118258931B (zh) * | 2024-05-29 | 2024-08-16 | 山东第一医科大学附属省立医院(山东省立医院) | 用于预警女性动脉粥样硬化的代谢标志物组合及检测试剂盒 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5264026B2 (ja) * | 1997-06-10 | 2013-08-14 | エルパス・インコーポレイテッド | 心疾患の早期発見のための方法 |
| WO2001065257A2 (de) | 2000-03-03 | 2001-09-07 | Gerd Schmitz | Verfahren zur analyse von exogener und endogener zell-aktivierung |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| WO2002062207A2 (en) | 2001-01-02 | 2002-08-15 | The Cleveland Clinic Foundation | Myeloperoxidase, a risk indicator for cardiovascular disease |
| JP4062514B2 (ja) | 2001-01-02 | 2008-03-19 | ザ・クリーブランド・クリニック・ファンデーション | ミエロペルオキシダーゼ、心臓血管疾患についての危険性指示因子 |
| WO2003005628A2 (en) * | 2001-07-06 | 2003-01-16 | Lipomics Technologies, Inc. | Generating, viewing, interpreting, and utilizing a quantitative database of metabolites |
| US7539588B2 (en) | 2002-06-28 | 2009-05-26 | Nxp B.V. | Data carrier with detection means for detecting a change made of information stored with storing means |
| WO2004038381A2 (en) | 2002-10-25 | 2004-05-06 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| EP1615990A2 (en) * | 2003-03-28 | 2006-01-18 | Washington University in St. Louis | Multidimensional mass spectrometry of serum and cellular lipids directly from biologic extracts |
| US20070244076A1 (en) * | 2003-10-08 | 2007-10-18 | Musc Foundation Research Development | Site and Rate Selective Prodrug Formulations of D609 with Antioxidant and Anticancer Activity |
| CA2548313A1 (en) | 2003-12-23 | 2005-07-14 | Musc Foundation For Research Development | Methods and compositions for the prevention and treatment of inflammatory diseases or conditions |
| WO2005095955A1 (en) * | 2004-03-31 | 2005-10-13 | Children, Youth And Women's Health Service | Screening for lysosomal storage disease status |
| EP1618876A1 (en) | 2004-07-19 | 2006-01-25 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Use of sphingolipids for prevention and treatment of atherosclerosis |
| FI20041340A0 (fi) * | 2004-10-15 | 2004-10-15 | Jurilab Ltd Oy | Menetelmä ja testipakkaus äkillisen sydäninfarktin riskin havaitsemiseksi |
| US20060135497A1 (en) * | 2004-12-17 | 2006-06-22 | Ajay Gupta | Combination therapy for treating heart disease |
| JP2008531603A (ja) | 2005-03-03 | 2008-08-14 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | 脂質低下特性を有する化合物 |
| EP1726962A1 (en) * | 2005-05-24 | 2006-11-29 | Leiden University Medical Center | Apolipoprotein E plasma levels for monitoring and reducing the risk of cardiovascular disease |
| BRPI0616720A2 (pt) * | 2005-09-28 | 2011-06-28 | Becton Dickinson Co | método para o diagnóstico ou prognóstico de sepse em um paciente, kit para diagnóstico ou prognóstico, ou monitoração, de sepse em um paciente, e, dispositivo para o diagnóstico ou prognóstico de sepse |
| US7972802B2 (en) | 2005-10-31 | 2011-07-05 | University Of Washington | Lipoprotein-associated markers for cardiovascular disease |
| WO2007127192A2 (en) * | 2006-04-24 | 2007-11-08 | Duke University | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| US8137977B2 (en) * | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| CN101522910A (zh) * | 2006-06-12 | 2009-09-02 | 佐拉生物科学有限公司 | 肌病的诊断方法 |
| WO2007144467A1 (en) * | 2006-06-12 | 2007-12-21 | Zora Biosciences Oy | Diagnostic method for myopathy |
| JP4611941B2 (ja) | 2006-06-29 | 2011-01-12 | トヨタ自動車株式会社 | 内燃機関の排気還流装置 |
| DE102006034153B4 (de) | 2006-07-24 | 2018-02-08 | Magna powertrain gmbh & co kg | Getriebe |
| EP3285072B1 (en) * | 2006-08-08 | 2020-04-15 | Metabolon, Inc. | Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof |
| CN101529248A (zh) * | 2006-09-14 | 2009-09-09 | 佐拉生物科学有限公司 | 作为用于早期预测自身免疫和1型糖尿病风险之工具的生物流体代谢物谱分析 |
| US8321154B2 (en) | 2007-03-26 | 2012-11-27 | Bg Medicine, Inc. | Methods for detecting coronary artery disease |
| WO2008148857A1 (en) | 2007-06-07 | 2008-12-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for assessing the risk of a cardiovascular disease and for diagnosing dyslipidemia |
| US8026099B2 (en) * | 2007-07-26 | 2011-09-27 | Washington University | Lipid profile as a biomarker for early detection of neurological disorders |
| WO2009132082A2 (en) * | 2008-04-22 | 2009-10-29 | Medical College Of Georgia Research Institute, Inc. | Immunogenic compositions containing ceramide and methods of use thereof |
| US10241093B2 (en) * | 2009-05-28 | 2019-03-26 | The Cleveland Clinic Foundation | Trimethylamine-containing compounds for diagnosis and prediction of disease |
| WO2011063470A1 (en) † | 2009-11-27 | 2011-06-03 | Baker Idi Heart And Diabetes Institute Holdings Limited | Lipid biomarkers for stable and unstable heart disease |
| EP2529235B1 (en) * | 2010-01-29 | 2019-03-06 | Metanomics GmbH | Means and methods for diagnosing heart failure in a subject |
| NO2385374T3 (https=) | 2010-05-05 | 2014-06-07 |
-
2010
- 2010-05-05 NO NO10162066A patent/NO2385374T3/no unknown
- 2010-05-05 DK DK10162066.4T patent/DK2385374T4/en active
- 2010-05-05 ES ES10162066.4T patent/ES2455124T5/es active Active
- 2010-05-05 EP EP10162066.4A patent/EP2385374B2/en active Active
-
2011
- 2011-05-05 DK DK11719802.8T patent/DK2567240T4/da active
- 2011-05-05 CN CN201180032921.0A patent/CN102971633B/zh active Active
- 2011-05-05 EP EP11719802.8A patent/EP2567240B2/en active Active
- 2011-05-05 EP EP18165052.4A patent/EP3399318B1/en active Active
- 2011-05-05 NO NO11719802A patent/NO2567240T3/no unknown
- 2011-05-05 JP JP2013508512A patent/JP5871244B2/ja active Active
- 2011-05-05 CA CA2798238A patent/CA2798238C/en active Active
- 2011-05-05 ES ES11719802T patent/ES2672054T5/es active Active
- 2011-05-05 WO PCT/EP2011/057254 patent/WO2011138419A1/en not_active Ceased
- 2011-05-05 US US13/695,766 patent/US9046538B2/en active Active
-
2015
- 2015-05-14 US US14/712,422 patent/US9459264B2/en active Active
-
2016
- 2016-08-25 US US15/246,851 patent/US9857386B2/en active Active
-
2017
- 2017-12-07 US US15/834,879 patent/US10551394B2/en active Active
-
2019
- 2019-12-16 US US16/715,801 patent/US12025623B2/en active Active
-
2024
- 2024-05-21 US US18/669,809 patent/US20240385201A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013527449A5 (https=) | ||
| JP2013531238A5 (https=) | ||
| CA2798238A1 (en) | Lipidomic biomarkers for atherosclerosis and cardiovascular disease | |
| JP2014532885A5 (https=) | ||
| Saito et al. | A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia | |
| Gniadecki et al. | Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris | |
| Seliger et al. | HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients | |
| Girerd et al. | Middle-aged men with increased waist circumference and elevated C-reactive protein level are at higher risk for postoperative atrial fibrillation following coronary artery bypass grafting surgery | |
| Kotseva et al. | Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey | |
| Zhao et al. | Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease | |
| Braun et al. | Lp-PLA2: a new target for statin therapy | |
| Canadian Diabetes Association Clinical Practice Guidelines Expert Committee | Dyslipidemia in adults with diabetes | |
| Wadström et al. | Elevated remnant and LDL cholesterol and the risk of peripheral artery disease: a Mendelian randomization study | |
| EP3635411B1 (en) | Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in individual patients | |
| Delluc et al. | Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism | |
| US10184932B2 (en) | Use of ceramides and LPLs in diagnosing CVD | |
| Landray et al. | Abnormal low‐density lipoprotein subfraction profile in patients with untreated hypertension | |
| Lawrence et al. | The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes | |
| Inami et al. | Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia | |
| Schweitzer et al. | A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus | |
| Yokote et al. | 12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia―Data From a Real-World Observational Study of Evolocumab in Japan― | |
| Hirsch et al. | Usefulness of non–high-density lipoprotein cholesterol determinations in the diagnosis and treatment of dyslipidemia | |
| Curtiss et al. | Medical evaluation of African American women entering drug treatment | |
| Tani et al. | Association of the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and body mass index with coronary plaque regression | |
| Lee et al. | Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong |